Navigation Links
3SBio Inc. Schedules Unaudited First Quarter 2011 Results
Date:5/3/2011

SHENYANG, China, May 3, 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release its first quarter 2011 unaudited financial results after the NASDAQ stock market  closes on Wednesday, May 11, 2011 at 8:00pm (US Eastern ).

Following the earnings announcement, 3SBio's senior management will host a conference call at 5:00am (US Pacific) / 8:00am (US Eastern) / 8:00pm (Beijing) on Thursday, May 12, 2011 to discuss its first quarter 2011  unaudited financial results and recent business activity. The conference call may be accessed using the dial-in numbers below:

Conference ID: 64963899

Local dial-in:China landline  

800-819-0121China mobile

400-620-8038Hong Kong  

852-2475-0994International toll-free dial-in:Hong Kong

800930346United Kingdom  

080-8234-6646United States  

1-866-519-4004International toll dial-in: 65 6723 9381

Replay- Conference ID: 64963899

A telephone replay will be available two hours after the call until May 19, 2011 at:

International dial-in:

61-2-8235-5000United States dial-in:

1-866-214-5335WebcastA live webcast of the conference will be available on the investor relations page of 3SBio's website at http://bbs.3sbio.com/en/News/xinvestors.aspx and at http://tinyurl.com/3SBio2011Q1

A replay of the webcast will be available within one hour after the conclusion of the call.

About 3SBio Inc.3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, develop
'/>"/>

SOURCE 3SBio Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. 3SBio Inc. Announces Second Quarter 2008 Results
2. 3SBio Inc. to Hold Annual General Meeting
3. 3SBio Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference
4. 3SBio Inc. Announces Results of Annual General Meeting
5. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
6. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
7. 3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008
8. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
9. 3SBio Inc. Files for SFDA Approval of NuLeusin
10. 3SBio Inc. Announces Third Quarter 2008 Results
11. 3SBio Inc. to Present at the Piper Jaffray 20th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... N.J. , March 30, 2015  New Jersey ... innovation projects in the state of New ... next round of grant funding, announced James M. ... Jersey Health Foundation Research Grants program, an additional $500,000 ... each to fund early stage research projects that demonstrate ...
(Date:3/30/2015)... , March 30, 2015 CASI Pharmaceuticals, ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a commercial focus on ... and Drug Administration (CFDA) has approved the Company,s application ... ovarian clear cell carcinoma (OCCC) patients for its proprietary ...
(Date:3/30/2015)... GERMANTOWN, Md. , March 30, 2015  /PRNewswire/ ... a leader in synthetic biology, and Merck Serono, ... Germany , today announced an exclusive ... commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. ... to develop innovative therapies that modulate the immune ...
(Date:3/30/2015)... (PRWEB) March 29, 2015 A two-day ... United States and plenary talks by four leading photonics ... Optics + Optoelectronics next month in Prague, Czech ... in 17 conferences alongside a two-day exhibition. Sponsored by ... , the event will run 13-16 April in the ...
Breaking Biology Technology:New Jersey Health Foundation Announces An Additional $1 Million To Fund Innovation and Research Grants in New Jersey 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3
... India remain hot, as VCs face more competition from private ... ... Venture capitalists will largely,direct their investments to the greentech and biotech ... for venture,funds, according to a recent survey by the U.S. audit, ...
... CRY ),a biomaterials, medical device and tissue processing company, ... results will be,released on Thursday, February 21, 2008. The ... 10:00 a.m. Eastern Time, February,21, 2008, to discuss the ... Steven G. Anderson, president and chief executive officer of,CryoLife, ...
... WALTHAM, Mass., Jan. 31 Repligen Corporation,(Nasdaq: ... Chief,Executive Officer, Walter C. Herlihy, Ph.D., will host a ... 11:00 a.m. EST, to report,third quarter fiscal year 2008 ... Company., This call is being webcast by Thomson/CCBN ...
Cached Biology Technology:Venture Capitalists Bullish on Greentech and Biotech, KPMG Study Says 2Venture Capitalists Bullish on Greentech and Biotech, KPMG Study Says 3CryoLife Announces Release Date and Teleconference Call Details for the Fourth Quarter and Year End 2007 Financial Results 2Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results 2Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results 3
(Date:3/24/2015)... 24, 2015   NexID Biometrics LLC, whose ... needs, today announced the beginning of shipments of version ... The company, based in Potsdam, N.Y. ... Connect:ID Expo, which began here today at the Walter ... 2.0 of its SDK boosts the accuracy rate range ...
(Date:3/23/2015)... LOS ANGELES , March 23, 2015  In ... in Federal fraud case conviction losses. This figure accounts ... fraud, which, according to The Nilson Report, exceeds $11 ... an investigative tool after a crime has occurred. Investor ... Agent and polygraph expert Joe Paolella partnered ...
(Date:3/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces its biometric payment ... products featured in 2015 "I Want That" International CES ... on the DIY Network.   DIY,s "I ... , site of the 2015 International CES for a ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... Liverpool are developing a new plant-based product that could replace fishmeal, ... at a time when more than 90% of EU waters are ... to satisfy consumer need for fish in an expanding human population, ... 1.9 million tonnes by 2035. Currently farmed fish, such ...
... , AURORA, Colo. (May 14, 2012) - Why does ... published by a University of Colorado School of Medicine researcher ... anorexic women and desensitized in obese women. The findings also ... involved in addictions. Guido Frank, MD, assistant professor ...
... out scientifically valid virtual experiments. The method yields insights ... to research from the University of Gothenburg, Sweden. ... from the Swedish town of Lysekil for one year. ... Inquiry to Insight., Using scientific data provided by the ...
Cached Biology News:New product to replace fishmeal could help prevent global food shortage 2Real science in virtual school labs 2
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
Mouse monoclonal [RIZ1723] to PRDM2/RIZ...
MagSi uniform silica particles coated with a carboxyl group containing polymer, covalently attached to the bead surface....
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
Biology Products: